US stock movement: Mesoblast surged on October 29th with net income up 44%, Ryoncil volume increase, and advances in cell therapy.

Mesoblast October 29th: Surge Analysis

Keywords: Net income up 44%, Ryoncil volume growth, cell therapy

1. On October 28, 2026, the company released its activity report for the first fiscal quarter ending September 30. Net income increased by 44% year-on-year, Ryoncil net income was $28 million, up 44% year-on-year, and the number of new patient initiations in September reached a monthly record high.

2. On October 28, 2026, first fiscal quarter net operating cash outflow was $2.1 million, an 86% improvement from $14.9 million in the same period last year; cash on hand at period end was $99 million.

3. On October 28, 2026, the registration trial of Ryoncil for adult SR-aGvHD has commenced and is recruiting patients. Up to 40 US sites are expected to be activated this year, covering around 60% of the approximately 8,500 annual adult allogeneic bone marrow transplant patients in the United States.

4. On October 28, 2026, all 350 patients in the pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for the treatment of inflammatory chronic low back pain have completed treatment; a positive meeting was held with the FDA regarding the BLA plan for the prevention of GI bleeding in end-stage heart failure patients with LVADs.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)